NC-6301, a polymeric micelle rationally optimized for effective release of docetaxel, is potent but is less toxic than native docetaxel in vivo

International Journal of Nanomedicine

Volumn 7, Issue , 2012, Pages 2713-2727

  Harada, Mitsunori ^a   Iwata, Caname ^b   Saito, Hiroyuki ^a   Ishii, Kenta ^a   Hayashi, Tatsuyuki ^a   Yashiro, Masakazu ^c   Hirakawa, Kosei ^c   Miyazono, Kohei ^b   Kato, Yasuki ^a   Kano, Mitsunobu R ^b  

^a NanoCarrier Co Ltd   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c Osaka City University   (Japan)

Author keywords

Breast cancer; Drug release; Gastric cancer

Indexed keywords

ANTINEOPLASTIC AGENT; DOCETAXEL; NC 6031; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CANCER INHIBITION; CONTROLLED STUDY; COVALENT BOND; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG POTENCY; DRUG RELEASE; DRUG STRUCTURE; DRUG TUMOR LEVEL; EXPERIMENTAL MONKEY; FEMALE; FOOD INTAKE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LIVER TOXICITY; LYMPH NODE METASTASIS; MALE; MOLECULAR INTERACTION; MOUSE; NEUTROPHIL COUNT; NONHUMAN; PROCESS OPTIMIZATION; STOMACH CARCINOMA; STRUCTURE ANALYSIS; TISSUE DISTRIBUTION; TOXICITY TESTING; TRIPLE NEGATIVE BREAST CANCER;

ANIMALS; ANTINEOPLASTIC AGENTS; BODY WEIGHT; CELL LINE, TUMOR; DRUG DELIVERY SYSTEMS; EATING; FEMALE; HUMANS; MACACA FASCICULARIS; MALE; MICE; MICE, NUDE; MICELLES; MULTIVARIATE ANALYSIS; NANOPARTICLES; NEOPLASMS, EXPERIMENTAL; PARTICLE SIZE; PEPTIDES; POLYETHYLENE GLYCOLS; TAXOIDS; TISSUE DISTRIBUTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

ANIMALIA; MACACA FASCICULARIS; MUS; MUS MUSCULUS;

EID: 84870347285     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S31247     Document Type: Article

References (39)

1. Kataoka K, Kwon GS, Yokoyama M, Okano T, Sakurai Y. Block copolymer micelles as vehicles for drug delivery. J Control Release. 1993;24(1-3):119-132.
2. Kwon GS, Kataoka K. Block copolymer micelles as long-circulating drug vehicles. Adv Drug Deliv Rev. 1995;16(2-3):295-309.
3. Kataoka K, Harada A, Nagasaki Y. Block copolymer micelles for drug delivery: design, characterization and biological significance. Adv Drug Deliv Rev. 2001;47(1):113-131.
4. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 1986;46(12 Pt 1): 6387-6392.
5. Veronese FM, Schiavon O, Pasut G, etal. PEG-doxorubicin conjugates: influence of polymer structure on drug release, in vitro cytotoxicity, biodistribution, and antitumor activity. Bioconjug Chem. 2005;16(4): 775-784.
6. Harada M, Bobe I, Saito H, etal. Improved anti-tumor activity of stabilized anthracycline polymeric micelle formulation, NC-6300. Cancer Sci. 2011;102(1):192-199.
7. Swain SM, Jeong JH, Geyer CE Jr, etal. Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer. N Engl J Med. 2010; 362(22):2053-2065.
8. Naito S, Tsukamoto T, Koga H, etal. Docetaxel plus prednisolone for the treatment of metastatic hormone-refractory prostate cancer: a multicenter phase II trial in Japan. Jpn J Clin Oncol. 2008;38(5):365-372.
9. Posner MR, Hershock DM, Blajman CR, etal. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med. 2007;357(17):1705-1715.
10. Ozdemir NY, Abali H, Oksüzǒgu B, etal. The efficacy and safety of reduced-dose docetaxel, cisplatin, and 5-fluorouracil in the first-line treatment of advanced stage gastric adenocarcinoma. Med Oncol. 2010;27(3):680-684.
11. Dorr RT. Pharmacology of the taxanes. Pharmacotherapy. 1997;17(5 Pt 2):96S-104S.
12. Katsumata N, Noda K, Nozawa S, etal. Phase II trial of docetaxel in advanced or metastatic endometrial cancer: a Japanese cooperative study. Br J Cancer. 2005;93(9):999-1004.
13. Okada S, Sakata Y, Matsuno S, etal. Phase II study of docetaxel in patients with metastatic pancreatic cancer: a Japanese cooperative study. Br J Cancer. 1999;80(3-4):438-443.
14. Yokoyama M, Miyauchi M, Yamada N, etal. Polymer micelles as novel drug carrier: Adriamycin-conjugated poly(ethylene glycol)-poly(aspartic acid) block copolymer. J Control Release. 1990;11(1-3):269-278.
15. Harada M, Saito H, Kato Y, inventors; NanoCarrier Co, Ltd, assignee. Docetaxel polymer derivative, method for producing same and use of same. PCT patent application WO 2009/142326A1. 2009.
16. Jackson JK, Gleave ME, Yago V, Beraldi E, Hunter WL, Burt HM. The suppression of human prostate tumor growth in mice by the intratumoral injection of a slow-release polymeric paste formulation of paclitaxel. Cancer Res. 2000;60(15):4146-4151.
17. Chipman SD, Oldham FB, Pezzoni G, Singer JW. Biological and clinical characterization of paclitaxel poliglumex (PPX, CT-2103), a macromolecular polymer-drug conjugate. Int J Nanomedicine. 2006;1(4):375-383.
18. Clarke SJ, Rivory LP. Clinical pharmacokinetics of docetaxel. Clin Pharmacokinet. 1999;36(2):99-114.
19. Sanofi-Aventis [homepage on the Internet]. Available from: http://di.sanofi-aventis.co.jp/interview/taxotere.pdf.
20. Plummer R, Wilson RH, Calvert H, etal. A phase I clinical study of cisplatin-incorporated polymeric micelles (NC-6004) in patients with solid tumours. Br J Cancer. 2011;104(4):593-598.
21. US Food and Drug Administration (FDA). Oncology tools: dose calculator [online tool]. Silver Spring, MD: FDA. Available from: http://www.accessdata.fda.gov/scripts/cder/onctools/animalquery.cfm.
22. Fujihara T, Sawada T, Hirakawa K, etal. Establishment of lymph node metastatic model for human gastric cancer in nude mice and analysis of factors associated with metastasis. Clin Exp Metastasis. 1998;16(4):389-398.
23. Hill BT, Whelan RD, Shellard SA, McClean S, Hosking LK. Differential cytotoxic effects of docetaxel in a range of mammalian tumor cell lines and certain drug resistant sublines in vitro. Invest New Drugs. 1994;12(3):169-182.
24. Lavelle F, Bissery MC, Combeau C, Riou JF, Vrignaud P, André S. Preclinical evaluation of docetaxel (Taxotere). Semin Oncol. 1995;22(2 Suppl 4):3-16.
25. Lokich J, Anderson N. Dose intensity for bolus versus infusion chemotherapy administration: review of the literature for 27 anti-neoplastic agents. Ann Oncol. 1997;8(1):15-25.
26. Bradshaw-Pierce EL, Eckhardt SG, Gustafson DL. A physiologically based pharmacokinetic model of docetaxel disposition: from mouse to man. Clin Cancer Res. 2007;13(9):2768-2776.
27. Hamaguchi T, Kato K, Yasui H, etal. A phase I and pharmacokinetic study of NK105, a paclitaxel-incorporating micellar nanoparticle formulation. Br J Cancer. 2007;97(2):170-176.
28. Hippo Y, Yashiro M, Ishii M, etal. Differential gene expression profiles of scirrhous gastric cancer cells with high metastatic potential to peritoneum or lymph nodes. Cancer Res. 2001;61(3):889-895.
29. Yashiro M, Hirakawa K. Cancer-stromal interactions in scirrhous gastric carcinoma. Cancer Microenviron. 2010;3(1):127-135.
30. Nishiyama M, Wada S. Docetaxel: its role in current and future treatments for advanced gastric cancer. Gastric Cancer. 2009;12(3):132-141.
31. Bruno R, Hille D, Riva A, etal. Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol. 1998;16(1):187-196.
32. Gianni L, Kearns CM, Giani A, etal. Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J Clin Oncol. 1995;13(1):180-190.
33. Kano MR, Bae Y, Iwata C, etal. Improvement of cancer-targeting therapy, using nanocarriers for intractable solid tumors by inhibition of TGF-beta signaling. Proc Natl Acad Sci U S A. 2007;104(9):3460-3465.
34. Chabottaux V, Sounni NE, Pennington CJ, etal. Membrane-type 4matrix metalloproteinase promotes breast cancer growth and metastases. Cancer Res. 2006;66(10):5165-5172.
35. Hervé M-A, Buteau-Lozano H, Vassy R, etal. Overexpression of vascular endothelial growth factor 189in breast cancer cells leads to delayed tumor uptake with dilated intratumoral vessels. Am J Pathol. 2008;172(1):167-178.
36. Liu J, Zahedi P, Zeng F, Allen C. Nano-sized assemblies of a PEG-docetaxel conjugate as a formulation strategy for docetaxel. J Pharm Sci. 2008;97(8):3274-3290.
37. Esmaeili F, Dinarvand R, Ghahremani MH, etal. Docetaxel-albumin conjugates: preparation, in vitro evaluation and biodistribution studies. J Pharm Sci. 2009;98(8):2718-2730.
38. Mikhail AS, Allen C. Poly(ethylene glycol)-b-poly(epsilon-caprolactone) micelles containing chemically conjugated and physically entrapped docetaxel: synthesis, characterization, and the influence of the drug on micelle morphology. Biomacromolecules. 2010;11(5):1273-1280.
39. Nektar Therapeutics [homepage on the Internet]. Available from: http://www.nektar.com/product_pipeline/oncology_nktr-105.html, accessed July 21, 2010.